A new triple-combination gel has arrived in the acne treatment landscape with meaningful efficacy data from Phase 3 clinical trials. Cabtreo, approved by the FDA in October 2023, combines clindamycin, adapalene, and benzoyl peroxide in a single formulation—the first of its kind. While the specific “68% total lesion count reduction” claim circulating online cannot be verified against published trial data, the actual Phase 3 results are significant: inflammatory lesions dropped by 80.1% and non-inflammatory lesions by 73.3% in the larger study population, compared to placebo.
This article explores what these verified trial results actually mean, how Cabtreo works, who benefits most from it, and what realistic expectations patients should have when starting this treatment. The approval of Cabtreo represents a shift in acne treatment strategy—combining three evidence-based ingredients in one product rather than requiring patients to layer multiple prescriptions. The trials involved 12 weeks of treatment with patients aged 12 and older, and the data shows measurable improvement across different lesion types. Understanding the actual numbers behind the headlines helps you make an informed decision about whether this treatment fits your skin care needs.
Table of Contents
- What Is This Triple-Combination Gel and How Is It Different from Other Acne Treatments?
- What Do the Phase 3 Trial Results Actually Show?
- How Does Cabtreo Compare to Using Adapalene and Benzoyl Peroxide Separately?
- Who Is the Best Candidate for Cabtreo, and When Should You Consider It?
- What Side Effects and Irritation Should You Expect?
- What’s the Timeline for Results, and What Should You Expect?
- What Does This Mean for the Future of Acne Treatment?
- Conclusion
What Is This Triple-Combination Gel and How Is It Different from Other Acne Treatments?
Cabtreo is a prescription topical gel containing three active ingredients: clindamycin 1.2%, adapalene 0.15%, and benzoyl peroxide 3.1%. Clindamycin is an antibiotic that reduces acne-causing bacteria. Adapalene is a retinoid that normalizes skin cell turnover and reduces inflammation. Benzoyl peroxide is an antimicrobial and keratolytic agent that prevents bacterial resistance and helps exfoliate dead skin cells.
By combining all three, the gel addresses acne through multiple mechanisms simultaneously—bacterial reduction, inflammation management, and cellular turnover—which is why it’s called a “triple combination.” The key difference from previous treatments is convenience and potentially improved adherence. Previously, patients often used adapalene from one product, benzoyl peroxide from another, and possibly an antibiotic prescription from a third. Cabtreo requires just one application, reducing complexity and the chance of application errors. The FDA approved it specifically for patients 12 years and older with acne, making it available for both teens and adults. However, this concentrated formulation also means higher active ingredient concentrations in a single product, which can increase irritation potential—something we’ll address in more detail later.
What Do the Phase 3 Trial Results Actually Show?
The FDA approval of Cabtreo was based on two Phase 3 trials, each 12 weeks long, comparing the gel to placebo. In the larger study (Study 2), patients using Cabtreo achieved an 80.1% reduction in inflammatory lesions—the red, tender pimples and nodules—compared to a 56.2% reduction in the placebo group. For non-inflammatory lesions (blackheads and whiteheads), the reduction was 73.3% with Cabtreo versus 49.0% with placebo. These percentage reductions represent the change from baseline counts, showing that Cabtreo worked better than doing nothing, and better than placebo alone.
The clinical efficacy endpoint measured in these trials was the “IGA Success Rate”—essentially, how many patients achieved nearly clear or clear skin by week 12. In Study 2, 49.6% to 50.5% of patients using Cabtreo achieved this level of success, compared to 20.5% to 24.9% in the placebo group. This is an important distinction: while the gel reduced lesion counts substantially, roughly half of trial participants reached a treatment success threshold, which means the other half had improvement but may not have achieved near-clear skin. This is realistic data—acne treatment rarely works perfectly for everyone, and individual results vary significantly.
How Does Cabtreo Compare to Using Adapalene and Benzoyl Peroxide Separately?
Many dermatologists have long recommended combining adapalene (available as Differin) with benzoyl peroxide—either by layering products or using combination formulations. Cabtreo adds clindamycin to this pairing, creating a three-pronged approach. The clinical advantage is that clindamycin provides immediate antimicrobial activity while adapalene and benzoyl peroxide work over several weeks to normalize skin and prevent resistance. For patients with moderate acne, particularly those with inflammatory lesions, this three-component approach may work faster than the two-component combination.
However, a direct head-to-head trial comparing Cabtreo to traditional adapalene-plus-benzoyl peroxide therapy (without the antibiotic) wasn’t the basis for FDA approval, so we can’t definitively say Cabtreo outperforms that combination. Additionally, the inclusion of clindamycin raises a consideration: antibiotic resistance. Using antibiotics on the skin long-term can select for resistant bacteria, which is why many dermatologists recommend using retinoids and benzoyl peroxide without antibiotics whenever possible. Cabtreo is FDA-approved for topical use, but patients should be aware that combining this with oral antibiotics would represent a higher overall antibiotic exposure.
Who Is the Best Candidate for Cabtreo, and When Should You Consider It?
Cabtreo works best for patients with moderate acne involving both inflammatory and non-inflammatory lesions. If your acne is primarily comedonal (blackheads and whiteheads) without much inflammation, a retinoid alone or retinoid-plus-benzoyl-peroxide might be sufficient and simpler to start with. If your acne is severe with cystic lesions or is widespread on the trunk, oral medications like isotretinoin or hormonal treatments might be more appropriate. Cabtreo is positioned as a mid-range prescription for patients who need more than over-the-counter options but don’t require systemic therapy.
Age also matters: Cabtreo is approved for ages 12 and up. Younger teens with developing skin might benefit from starting with gentler options, but moderate acne in teen years is exactly what this product targets. Adults with persistent acne also fit the profile. The treatment requires consistent nightly application for at least 12 weeks to see meaningful results—the trials showed efficacy at 12 weeks, but improvement often continues beyond that point. This means you need commitment and patience; seeing benefit in 3-4 weeks is unlikely, and expecting clear skin in that timeframe will lead to disappointment.
What Side Effects and Irritation Should You Expect?
Because Cabtreo contains three active ingredients at meaningful concentrations, irritation is the most common side effect. In clinical trials, patients reported redness, dryness, peeling, and mild stinging, particularly in the first 2-4 weeks as skin adapts. Adapalene is a retinoid and causes retinization—the adjustment period where skin may appear worse before improving. Adding clindamycin doesn’t significantly increase irritation over adapalene-plus-benzoyl-peroxide, but the combination is stronger than any single ingredient alone.
A critical warning: if you have very sensitive skin, rosacea, or are currently using other retinoids or strong peeling agents, Cabtreo may be too irritating to use daily. Starting with reduced frequency (every other night) or stopping other irritating products first is necessary. Additionally, Cabtreo can increase sun sensitivity, so daily SPF 30+ sunscreen is mandatory, even on cloudy days. Some patients also experience contact allergy to one of the components—clindamycin allergy is rare but possible, and benzoyl peroxide can trigger irritant or allergic reactions in a small percentage of users. If your skin feels increasingly raw or develops hives after starting, discontinue and contact your dermatologist.
What’s the Timeline for Results, and What Should You Expect?
The Phase 3 trials measured results at 12 weeks, so that’s the realistic minimum timeline for evaluating whether Cabtreo works for you. Most users see noticeable improvement in inflammatory lesions within 4-6 weeks, but this improvement is gradual—not the dramatic overnight change that acne sufferers hope for. Non-inflammatory lesions (comedones) typically take longer to resolve because they require sustained cell turnover from the adapalene component. Some patients report continued improvement at 16-20 weeks, beyond the 12-week trial endpoint.
Importantly, the approximately 50% “treatment success rate” in the trials means that even with consistent use, you may not achieve completely clear skin. You might go from 40 comedones and 20 inflamed pimples to 10 comedones and 3 pimples—significant improvement that meaningfully affects quality of life, but not perfection. Setting this expectation prevents the disappointment that leads patients to abandon treatment prematurely. Keeping a photo record from the start is helpful for tracking progress that might not be obvious day-to-day.
What Does This Mean for the Future of Acne Treatment?
Cabtreo’s FDA approval signals that the dermatology field is moving toward convenient, multi-target formulations. Rather than asking patients to manage three separate prescriptions with different application instructions, a single product addressing multiple mechanisms is easier to use correctly and likely improves real-world adherence. This matters because acne treatment fails in practice not because the drugs don’t work, but because patients stop using them due to irritation, complexity, or not seeing results fast enough.
The use of clindamycin in a fixed combination with benzoyl peroxide also addresses resistance concerns—benzoyl peroxide doesn’t allow resistance to develop, so combining it with clindamycin theoretically reduces the risk of antibiotic resistance that occurs when antibiotics are used alone. Future developments may include even more targeted combinations, such as pairing retinoids with different types of antimicrobials or anti-inflammatory agents. For now, Cabtreo represents the current standard for multi-component topical acne therapy.
Conclusion
The new triple-combination gel Cabtreo does deliver measurable efficacy in Phase 3 trials, with verified data showing significant reductions in both inflammatory and non-inflammatory lesions. However, the unverified “68% total lesion count reduction” claim highlights why reading actual trial results matters more than headlines. The real efficacy—80.1% inflammatory lesion reduction and approximately 50% treatment success rates—is meaningful but not miraculous, requiring 12 weeks of consistent use and realistic expectations.
If you have moderate acne with a mix of lesion types, are willing to tolerate some initial irritation, and can commit to 12 weeks of nightly application with rigorous sunscreen use, Cabtreo is worth discussing with your dermatologist. It offers convenience and a rational combination of proven ingredients. However, it’s not appropriate for everyone—those with very sensitive skin, mild comedonal acne, or severe cystic acne might benefit from different approaches. Your dermatologist can assess your specific situation and determine whether Cabtreo fits into your treatment plan.
